Chronos Archive seal
The Human Record

Lili Boulanger

Case HR-ET025 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
August 21, 1893 – March 15, 1918
Synthetic DOB
2004-08-21
Index visit
2026-01-19 at age 21
Synthetic MRN
HR-ET025-SYN

Teaching objective: Evaluate chronic abdominal pain, diarrhea, and weight loss in a young woman of 21: confirm Crohn disease by ileocolonoscopy with biopsies and MR enterography, and exclude intestinal tuberculosis before any immunosuppression (interferon-gamma release assay, chest X-ray, and biopsies for acid-fast bacilli, TB PCR, and culture); classify the disease (Montreal) and its risk; start an advanced therapy early for moderate to severe disease, with latent tuberculosis, hepatitis B, and vaccine preparation first; correct iron, vitamin D, and nutrition; protect bone; treat to target with CRP, fecal calprotectin, and endoscopy; plan contraception, fertility, and pregnancy; screen mood; and help her keep composing. The historical illness is graded R: called intestinal tuberculosis in her time and proposed to be Crohn disease since, it is not settled.

Historical timeline

DateEventClaims
August 21, 1893Born in Paris.CLM-0001, CLM-0002
1895Pneumonia at about two years old; frail health thereafter.CLM-0003, CLM-0004
1913First woman to win the Premier Grand Prix de Rome for composition, with Faust et Hélène.CLM-0005
1914Villa Medici in Rome; left for Nice when war broke out.CLM-0006
Early 1915In Paris: headaches, loss of appetite, fever, and colitis-like symptoms; much of the time in bed, still composing.CLM-0007
Late 1915With her sister, helped found the Franco-American Committee of the Conservatoire.CLM-0008
1916Second stay in Rome, then return to France.CLM-0006
July 1917Operation in Paris; later dictated her music to her sister.CLM-0011
March 15, 1918Died at Mézy-sur-Seine; her illness described as intestinal tuberculosis and later proposed to be Crohn disease.CLM-0012, CLM-0009, CLM-0010

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Lili Boulanger was born Marie-Juliette Olga Boulanger on August 21, 1893, in the 9th arrondissement of Paris.
Reference works give the given names in different orders (Juliette Marie Olga; Julie-Marie Olga); the national library's civil-register form is used.
confirmed Boulanger, Lili (1893-1918): authority record supports
Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia supports
Boulanger, Lili context
D She was a composer, the sister of the composer and teacher Nadia Boulanger (1887–1979). confirmed Boulanger, Lili (1893-1918): authority record supports
D At about two years old, in 1895, she had pneumonia, described as bronchial pneumonia; her health was frail from a very young age and she remained sickly for the rest of her life. confirmed Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) supports
Boulanger, Lili supports
Coduti CL. Who Was Lili Boulanger? The Story Behind Soir sur la Plaine supports
Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia supports
R The usual account is that the childhood pneumonia left her immune system weakened, so that she never fully recovered.
A biographical interpretation, not a documented immune diagnosis; no test of her immunity exists.
possible Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) supports
Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) context
D In 1913, at 19, she became the first woman to win the Premier Grand Prix de Rome for musical composition, with the cantata Faust et Hélène; she had been the only woman among the five finalists that May. confirmed Boulanger, Lili (1893-1918): authority record supports
Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia supports
Boulanger, Lili supports
Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) supports
D She went to the Villa Medici in Rome in 1914. The outbreak of war made her leave Rome for Nice, where she composed the song cycle Clairières dans le ciel; she stayed in Rome again in 1916 and then returned to France.
One source says she instead made an unauthorized return to Paris in the summer of 1914; the record does not rely on either detail.
confirmed Boulanger, Lili supports
Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports
Graham D. Lili Boulanger: in her tragically short life, she helped shape 20th-century music context
D Early in 1915, living in Paris, she began to have headaches, loss of appetite, and fever, followed by symptoms resembling colitis and appendicitis; she spent much of her time in bed but kept composing.
Reported in an encyclopedia article drawn from the Spycket biography, which was not read directly. The documented presentation that anchors the synthetic episode.
probable Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports
D During the war she and her sister helped to found the Franco-American Committee of the Conservatoire, which kept mobilized students in touch with the Conservatoire. confirmed Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports
R Her chronic intestinal illness has been described as intestinal tuberculosis, and several reference works give tuberculosis as the cause of her death.
No test from her lifetime confirming tuberculosis is reported in the sources read; whether she had intestinal tuberculosis is not settled.
disputed Coduti CL. Who Was Lili Boulanger? The Story Behind Soir sur la Plaine supports
Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia supports
Boulanger, Lili supports
Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) supports
R Later writers have proposed that her chronic intestinal illness was Crohn disease, which was not described as a distinct disease until well after her death.
A retrospective diagnosis in program notes, a music magazine, and an encyclopedia article; no peer-reviewed analysis was found. It conflicts with the tuberculosis account, and the cause of death is not settled.
disputed Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) supports
Graham D. Lili Boulanger: in her tragically short life, she helped shape 20th-century music supports
Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports
Coduti CL. Who Was Lili Boulanger? The Story Behind Soir sur la Plaine supports
D After her return to Paris in 1917 she had an operation at the end of July; the operation and its findings are not named in the source read. In her last illness, unable to hold a pen, she dictated her music to her sister.
Later than the synthetic episode and not used in it.
probable Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports
Graham D. Lili Boulanger: in her tragically short life, she helped shape 20th-century music supports
D She died on March 15, 1918, at Mézy-sur-Seine (Yvelines), at 24.
One reference biography places the death in Paris and another in the Paris area; the national library authority record gives Mézy-sur-Seine. Record the death as a fact without detail.
confirmed Boulanger, Lili (1893-1918): authority record supports
Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) supports
Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia disputes
Boulanger, Lili context

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settled active confirmed both_with_link CLM-0007, CLM-0009, CLM-0010
S Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging booked resolved confirmed active CLM-0007
S Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9) resolved confirmed active
S Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dL resolved confirmed active
S Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL) resolved confirmed active
S Long-term use of risankizumab, an immunosuppressive biologic, for Crohn disease active confirmed active
S Acute norovirus gastroenteritis on risankizumab, with mild dehydration; distinguished from a Crohn flare by the sudden onset, household contacts, and a positive stool PCR; resolved in three days resolved confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-01-19 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 2 http://loinc.org · 55758-7
S 2026-01-19 Hemoglobin [Mass/volume] in Blood 10.6 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-01-19 MCV [Entitic mean volume] in Red Blood Cells by Automated count 76 fL (low)
Reference 80-100 fL
http://loinc.org · 787-2
S 2026-01-19 Leukocytes [#/volume] in Blood by Automated count 9.8 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-01-19 Platelets [#/volume] in Blood by Automated count 452 10*3/uL (high)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-01-19 C reactive protein [Mass/volume] in Serum or Plasma 38 mg/L (high)
Reference <=5 mg/L
http://loinc.org · 1988-5
S 2026-01-19 Calprotectin [Mass/mass] in Stool 1240 ug/g (high)
Reference <=50 ug/g
http://loinc.org · 38445-3
S 2026-01-19 Albumin [Mass/volume] in Serum or Plasma 3.3 g/dL (low)
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-01-19 Ferritin [Mass/volume] in Serum or Plasma 9 ng/mL (low)
Reference 15-150 ng/mL
http://loinc.org · 2276-4
S 2026-01-19 Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 310 pg/mL
Reference 200-900 pg/mL
http://loinc.org · 2132-9
S 2026-01-19 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 18 ng/mL (low)
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-01-19 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 16 U/L
Reference <=33 U/L
http://loinc.org · 1742-6
S 2026-01-19 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 U/L
Reference <=32 U/L
http://loinc.org · 1920-8
S 2026-01-19 Creatinine [Mass/volume] in Serum or Plasma 0.7 mg/dL
Reference 0.5-1.1 mg/dL
http://loinc.org · 2160-0
S 2026-01-28 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 8 http://loinc.org · 44261-6
S 2026-01-28 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 9 http://loinc.org · 70274-6
S 2026-01-28 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 U/L
Reference <=33 U/L
http://loinc.org · 1742-6
S 2026-01-28 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 U/L
Reference <=32 U/L
http://loinc.org · 1920-8
S 2026-01-28 Bilirubin.total [Mass/volume] in Serum or Plasma 0.4 mg/dL
Reference <=1.2 mg/dL
http://loinc.org · 1975-2
S 2026-01-28 DXA Lumbar spine [Z-score] Bone density -1.4
Reference A Z-score of -2.0 or below is below the expected range for age
http://loinc.org · 85394-5
S 2026-01-28 DXA Femur [Z-score] Bone density -1.1
Reference A Z-score of -2.0 or below is below the expected range for age
http://loinc.org · 80934-3
S 2026-03-02 Hemoglobin [Mass/volume] in Blood 11.6 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-03-02 C reactive protein [Mass/volume] in Serum or Plasma 8 mg/L (high)
Reference <=5 mg/L
http://loinc.org · 1988-5
S 2026-03-02 Albumin [Mass/volume] in Serum or Plasma 3.7 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-03-02 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference <=33 U/L
http://loinc.org · 1742-6
S 2026-03-02 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference <=32 U/L
http://loinc.org · 1920-8
S 2026-03-02 Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 mg/dL
Reference <=1.2 mg/dL
http://loinc.org · 1975-2
S 2026-03-02 Phosphate [Mass/volume] in Serum or Plasma 3 mg/dL
Reference 2.5-4.5 mg/dL
http://loinc.org · 2777-1
S 2026-03-02 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 http://loinc.org · 44261-6
S 2026-03-02 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 6 http://loinc.org · 70274-6
S 2026-04-27 Hemoglobin [Mass/volume] in Blood 12.6 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-04-27 MCV [Entitic mean volume] in Red Blood Cells by Automated count 83 fL
Reference 80-100 fL
http://loinc.org · 787-2
S 2026-04-27 Ferritin [Mass/volume] in Serum or Plasma 86 ng/mL
Reference 15-150 ng/mL
http://loinc.org · 2276-4
S 2026-04-27 C reactive protein [Mass/volume] in Serum or Plasma 3 mg/L
Reference <=5 mg/L
http://loinc.org · 1988-5
S 2026-04-27 Calprotectin [Mass/mass] in Stool 210 ug/g (high)
Reference <=50 ug/g
http://loinc.org · 38445-3
S 2026-04-27 Albumin [Mass/volume] in Serum or Plasma 4.1 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-04-27 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 U/L
Reference <=33 U/L
http://loinc.org · 1742-6
S 2026-04-27 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 U/L
Reference <=32 U/L
http://loinc.org · 1920-8
S 2026-04-27 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference <=1.2 mg/dL
http://loinc.org · 1975-2
S 2026-04-27 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 ng/mL
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-08-03 Hemoglobin [Mass/volume] in Blood 13.1 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-08-03 Ferritin [Mass/volume] in Serum or Plasma 72 ng/mL
Reference 15-150 ng/mL
http://loinc.org · 2276-4
S 2026-08-03 Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 340 pg/mL
Reference 200-900 pg/mL
http://loinc.org · 2132-9
S 2026-08-03 C reactive protein [Mass/volume] in Serum or Plasma 2 mg/L
Reference <=5 mg/L
http://loinc.org · 1988-5
S 2026-08-03 Calprotectin [Mass/mass] in Stool 42 ug/g
Reference <=50 ug/g
http://loinc.org · 38445-3
S 2026-08-03 Albumin [Mass/volume] in Serum or Plasma 4.3 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-08-03 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 2026-04-13 Leukocytes [#/volume] in Blood by Automated count 9.4 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-04-13 C reactive protein [Mass/volume] in Serum or Plasma 11 mg/L (high)
Reference <=5 mg/L
http://loinc.org · 1988-5
S 2026-04-13 Potassium [Moles/volume] in Serum or Plasma 3.4 mmol/L (low)
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-04-13 Creatinine [Mass/volume] in Serum or Plasma 0.9 mg/dL
Reference 0.5-1.1 mg/dL
http://loinc.org · 2160-0
S 2026-04-13 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 U/L
Reference <=33 U/L
http://loinc.org · 1742-6
S 2026-10-19 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 2026-10-19 Total score [AUDIT-C] 0 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-01-19Body height160 cm8302-2S
2026-01-19Body weight45 kg29463-7S
2026-01-19Body mass index (BMI) [Ratio]17.6 kg/m239156-5S
2026-01-19Systolic blood pressure104 mm[Hg]8480-6S
2026-01-19Diastolic blood pressure66 mm[Hg]8462-4S
2026-01-19Heart rate96 /min8867-4S
2026-01-19Respiratory rate16 /min9279-1S
2026-01-19Body temperature37.6 Cel8310-5S
2026-01-19Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-01-28Body height160 cm8302-2S
2026-01-28Body weight44.8 kg29463-7S
2026-01-28Body mass index (BMI) [Ratio]17.5 kg/m239156-5S
2026-01-28Systolic blood pressure102 mm[Hg]8480-6S
2026-01-28Diastolic blood pressure64 mm[Hg]8462-4S
2026-01-28Heart rate92 /min8867-4S
2026-01-28Respiratory rate16 /min9279-1S
2026-01-28Body temperature37.4 Cel8310-5S
2026-01-28Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-03-02Body height160 cm8302-2S
2026-03-02Body weight46.4 kg29463-7S
2026-03-02Body mass index (BMI) [Ratio]18.1 kg/m239156-5S
2026-03-02Systolic blood pressure108 mm[Hg]8480-6S
2026-03-02Diastolic blood pressure68 mm[Hg]8462-4S
2026-03-02Heart rate84 /min8867-4S
2026-03-02Respiratory rate14 /min9279-1S
2026-03-02Body temperature36.8 Cel8310-5S
2026-03-02Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-04-27Body height160 cm8302-2S
2026-04-27Body weight48.4 kg29463-7S
2026-04-27Body mass index (BMI) [Ratio]18.9 kg/m239156-5S
2026-04-27Systolic blood pressure106 mm[Hg]8480-6S
2026-04-27Diastolic blood pressure68 mm[Hg]8462-4S
2026-04-27Heart rate76 /min8867-4S
2026-04-27Respiratory rate14 /min9279-1S
2026-04-27Body temperature36.7 Cel8310-5S
2026-04-27Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-08-03Body height160 cm8302-2S
2026-08-03Body weight50.6 kg29463-7S
2026-08-03Body mass index (BMI) [Ratio]19.8 kg/m239156-5S
2026-08-03Systolic blood pressure108 mm[Hg]8480-6S
2026-08-03Diastolic blood pressure70 mm[Hg]8462-4S
2026-08-03Heart rate72 /min8867-4S
2026-08-03Respiratory rate14 /min9279-1S
2026-08-03Body temperature36.6 Cel8310-5S
2026-08-03Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-04-13Body height160 cm8302-2S
2026-04-13Body weight46.9 kg29463-7S
2026-04-13Body mass index (BMI) [Ratio]18.3 kg/m239156-5S
2026-04-13Systolic blood pressure98 mm[Hg]8480-6S
2026-04-13Diastolic blood pressure62 mm[Hg]8462-4S
2026-04-13Heart rate98 /min8867-4S
2026-04-13Respiratory rate16 /min9279-1S
2026-04-13Body temperature37.7 Cel8310-5S
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-10-19Body height160 cm8302-2S
2026-10-19Body weight51.4 kg29463-7S
2026-10-19Body mass index (BMI) [Ratio]20.1 kg/m239156-5S
2026-10-19Systolic blood pressure108 mm[Hg]8480-6S
2026-10-19Diastolic blood pressure68 mm[Hg]8462-4S
2026-10-19Heart rate70 /min8867-4S
2026-10-19Respiratory rate14 /min9279-1S
2026-10-19Body temperature36.6 Cel8310-5S
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
Reach a diagnosis, with tuberculosis excluded, within two weeks2026-01-28completedIleocolonoscopy, biopsies, MR enterography, interferon-gamma release assay, and chest X-ray completed in nine days; Crohn disease diagnosed and intestinal tuberculosis made very unlikely, with the mycobacterial culture still pending
Steroid-free clinical remission by week 12 to 16 of treatment2026-04-27completedHarvey-Bradshaw Index 2 at week 12, five weeks after the prednisone taper ended
Normal CRP and fecal calprotectin by six months, and endoscopic response at six to twelve months2026-10-05completedCRP 2 mg/L and calprotectin 42 ug/g at six months; SES-CD 14 to 2 at eight months
Regain weight to a BMI of 19 or more and correct iron and vitamin D2026-08-03completedWeight 50.6 kg (BMI 19.8); hemoglobin 13.1, ferritin 72, vitamin D 34
Perform her March concert and keep composing through treatment2026-04-27completedComposing most mornings; the concert went ahead in late March with a plan for bathroom access

Interventions

InterventionStatusGuideline
Workup for suspected inflammatory bowel disease: blood count, CRP, albumin, iron studies, vitamin B12 and D, fecal calprotectin, stool tests for Clostridioides difficile and enteric pathogens, celiac serology, a pregnancy test, ileocolonoscopy with biopsies, and MR enterographycompletedGL-ACG-CD-2025, GL-ECCO-ESGAR-2019
Exclude intestinal tuberculosis before any steroid or immunosuppressive drug: interferon-gamma release assay, chest X-ray, and ileal and colonic biopsies for acid-fast stain, TB PCR, and mycobacterial culture; with hepatitis B, hepatitis C, HIV, measles, and varicella serology before treatmentcompletedGL-ECCO-INF-2026, GL-ACG-CD-2025
Gastroenterology (inflammatory bowel disease) consultation once the endoscopy and imaging are done, to confirm the diagnosis and choose treatment with hercompletedGL-ACG-CD-2025, GL-AGA-CD-2021
Nutrition: dietitian assessment, small frequent meals with oral nutritional supplements, and weight at every visitcompletedGL-ECCO-CD-2024, GL-ACG-PREV-2025
Mood, anxiety, and work: PHQ-9 and GAD-7 at intervals, IBD psychology if needed, and a practical plan for composing and performing during treatmentcompletedGL-ACG-PREV-2025
Risankizumab 600 mg intravenously at weeks 0, 4, and 8, then 360 mg subcutaneously every 8 weeks, chosen with her as early advanced therapy; liver enzymes and bilirubin at baseline and through at least week 12; a short prednisone bridge tapered over eight weeks; no live vaccinescompletedGL-ACG-CD-2025, GL-AGA-CD-2021, GL-ECCO-CD-2024, GL-FDA-RISANKIZUMAB-2026
Vaccines before immunosuppression: PCV20, recombinant zoster vaccine in two doses, a hepatitis B booster with an antibody check one to two months later, and influenza and COVID-19 vaccines each season; live vaccines not needed because she is immune to measles and varicellacompletedGL-ACG-PREV-2025, GL-CDC-IMZ-2026, GL-ECCO-INF-2026
Iron, vitamin D, and bone: one intravenous ferric derisomaltose infusion, vitamin D3 daily, calcium while on prednisone, baseline DXA, and weight-bearing exercisecompletedGL-ACG-PREV-2025, GL-ECCO-CD-2024
Treat to target: symptoms and CRP at every visit, fecal calprotectin at about three and six months, and ileocolonoscopy at six to twelve monthscompletedGL-STRIDE-2021, GL-ACG-CD-2025
Contraception, fertility, and pregnancy planning: effective contraception while the disease is active; plan pregnancy after three to six months of steroid-free remission, with a preconception review; continue the biologic in pregnancy after discussing the limited data for risankizumab; folic acid before conceptioncompletedGL-PREG-IBD-2025, GL-FDA-RISANKIZUMAB-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Boulanger, Lili (1893-1918): authority record Bibliothèque nationale de France government
SRC-0002 Boulanger, Lili (1893–1918). Women in World History: A Biographical Encyclopedia Encyclopedia.com (Gale) biography
SRC-0003 Boulanger, Lili Bru Zane Mediabase (Palazzetto Bru Zane, Centre de musique romantique française) biography
SRC-0004 Holland-Barry A. Lili Boulanger (21 August 1893–15 March 1918) RISM (Répertoire International des Sources Musicales) biography
SRC-0005 Ueda Y. Boulanger, Lili (based on Spycket J, À la recherche de Lili Boulanger, Fayard, 2004) PTNA Piano Encyclopedia biography
SRC-0006 Coduti CL. Who Was Lili Boulanger? The Story Behind Soir sur la Plaine Pacific Chorale other
SRC-0007 Graham D. Lili Boulanger: in her tragically short life, she helped shape 20th-century music BBC Music Magazine (classical-music.com) other
SRC-0008 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the exclusion of intestinal tuberculosis, the choice of risankizumab over an anti-TNF with an immunomodulator, the prednisone bridge, the vaccine plan, and the pregnancy counseling.
provenance reviewnot_startedDates, names, and the Prix de Rome from the Bibliothèque nationale de France authority record and reference biographies; the early-1915 symptoms from an encyclopedia article drawn from the Spycket biography; the intestinal tuberculosis and Crohn disease accounts graded R and disputed. Grove and the Fauser and Spycket works were not read directly. Her sister and mother appear only in documented claims.
safe messaging reviewnot_startedNo behavioral-health diagnosis; mild distress at diagnosis is screened and supported; death recorded without detail.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.